Pyxis Oncology (PYXS) Retained Earnings (2020 - 2025)
Pyxis Oncology (PYXS) reported Retained Earnings of -$443.2 million for Q4 2025, down 260805.88% year-over-year from N/an in Q4 2024, and down 4.26% quarter-over-quarter from -$425.1 million in Q3 2025.
Pyxis Oncology (PYXS) Retained Earnings (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 6 years of Retained Earnings data on file, last reported at -$443.2 million in Q4 2025.
- Retained Earnings for Q4 2025 came in at -$443.2 million, down 260805.88% year-over-year; the trailing twelve-month figure through Dec 2025 was -$443.2 million (down 260805.88% YoY), and the FY2025 annual result was -$443.2 million, down 260805.88% from the prior year.
- Retained Earnings eased to -$443.2 million in Q4 2025 per PYXS's latest filing, from -$425.1 million in the prior quarter.
- Over five years, Retained Earnings peaked at $696000.0 in Q1 2023 and troughed at -$443.2 million in Q4 2025.
- A 5-year average of -$143.2 million and a median of -$107.4 million in 2021 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings slumped 312266.67% in 2024, then jumped 181.67% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$91.7 million in 2021, then sank by 131.62% to -$212.4 million in 2022, then soared by 100.03% to $63000.0 in 2023, then soared by 169.84% to $170000.0 in 2024, then plunged by 260805.88% to -$443.2 million in 2025.
- Business Quant data shows PYXS's Retained Earnings at -$443.2 million in Q4 2025, -$425.1 million in Q3 2025, and -$5000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | -443.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -443.20 Mn |
| Sep 30, 2025 | -425.10 Mn |
| Jun 30, 2025 | -5,000.00 |
| Mar 31, 2025 | 49,000.00 |
| Dec 31, 2024 | 170,000.00 |
| Sep 30, 2024 | -327.99 Mn |
| Jun 30, 2024 | -306.80 Mn |
| Mar 31, 2024 | -60,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Sep 30, 2023 | -105,000.00 |
| Jun 30, 2023 | -247.58 Mn |
| Mar 31, 2023 | 696,000.00 |
| Dec 31, 2022 | -212.44 Mn |
| Sep 30, 2022 | -176.33 Mn |
| Jun 30, 2022 | -148.70 Mn |
| Mar 31, 2022 | -123.10 Mn |
| Dec 31, 2021 | -91.72 Mn |
| Sep 30, 2021 | -74.89 Mn |
| Dec 31, 2020 | -15.74 Mn |